Microdosing clinical study: Pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose

Journal of Clinical Pharmacology

Volumn 52, Issue 7, 2012, Pages 1078-1089

  Ieiri, Ichiro ^a   Doi, Yohei ^a   Maeda, Kazuya ^b   Sasaki, Tomohiro ^a   Kimura, Miyuki ^c   Hirota, Takeshi ^a   Chiyoda, Takeshi ^d   Miyagawa, Mayuko ^b   Irie, Shin ^c   Iwasaki, Kazuhide ^e   Sugiyama, Yuichi ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Kyushu Clinical Pharmacology Research Clinic   (Japan)

^d Sumida Hospital   (Japan)

^e SHIN NIPPON BIOMEDICAL LABORATORIES LTD   (Japan)

Author keywords

celiprolol; microdose; pharmacogenomics; SLCO2B1; therapeutic dose

Indexed keywords

ATENOLOL; CELIPROLOL; FEXOFENADINE; ORGANIC ANION TRANSPORTER; PROTEIN SLCO2B1; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG MICRODOSE; GENETIC POLYMORPHISM; GENOTYPE; GRAPEFRUIT JUICE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; MALE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; OPEN STUDY; PHARMACOGENOMICS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, ORAL; ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ADULT; AREA UNDER CURVE; ATENOLOL; BEVERAGES; CELIPROLOL; CITRUS PARADISI; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FOOD-DRUG INTERACTIONS; HUMANS; MALE; ORGANIC ANION TRANSPORTERS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; TERFENADINE; YOUNG ADULT;

EID: 84859707877     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011408612     Document Type: Article

References (44)

1. Committee for Medical Products for Human Use. Position Paper on Non-Clinical Safety Studies to Support Clinical Trials With a Single Microdose. London: European Medicines Agency; 2004. CPMP/SWP/2599/02/Rev. 1.
2. Food and Drug Administration. Guidance for Industry: Exploratory IND Studies. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 2006.
3. Combes RD, Berridge T, Connelly J, et al. Early microdose drug studies in human volunteers can minimise animal testing: proceedings of a workshop organised by Volunteers in Research and Testing. Eur J Pharm Sci. 2003;19:1-11. (Pubitemid 36506932)
4. Ministry of Health, Labour and Welfare. Guidance: Microdose Clinical Studies. Tokyo, Japan: Ministry of Health, Labour, and Welfare, Pharmaceutical and Medical Safety Bureau; 2008.
5. Riddell JG, Shanks RG, Brogden RN. Celiprolol: a preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris. Drugs. 1987;34:438-458. (Pubitemid 17143096)
6. Milne RJ, Buckley MM. Celiprolol: an updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease. Drugs. 1991;41:941-969. (Pubitemid 21920758)
7. Lilja JJ, Backman JT, Laitila J, Luurila H, Neuvonen PJ. Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin Pharmacol Ther. 2003;73:192-198. (Pubitemid 36269670)
8. Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther. 2002;71:11-20. (Pubitemid 34124034)
9. Banfield C, Gupta S, Marino M, Lim J, Affrime M. Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin Pharmacokinet. 2002;41:311-318. (Pubitemid 34533758)
10. Petri N, Tannergren C, Rungstad D, Lennernäs H. Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm Res. 2004;21:1398-1404. (Pubitemid 39149654)
11. Karlsson J, Kuo SM, Ziemniak J, Artursson P. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br J Pharmacol. 1993;110:1009-1016. (Pubitemid 24005233)
12. Sai Y, Kaneko Y, Ito S, et al. Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Drug Metab Dispos. 2006;34:1423-1431. (Pubitemid 44079886)
13. Meier Y, Eloranta JJ, Darimont J, et al. Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab Dispos. 2007;35:590-594. (Pubitemid 46513261)
14. Satoh H, Yamashita F, Tsujimoto M, et al. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2005;33:518-523. (Pubitemid 40393194)
15. Fuchikami H, Satoh H, Tsujimoto M, Ohdo S, Ohtani H, Sawada Y. Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2006;34: 557-582.
16. Mougey EB, Feng H, Castro M, Irvin CG, Lima JJ. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics. 2009;19:129-138.
17. Yamasaki Y, Ieiri I, Kusuhara H, et al. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. Clin Pharmacokinet Ther. 2008;84:95-103. (Pubitemid 351861490)
18. Ide T, Sasaki T, Maeda K, Higuchi S, Sugiyama Y, Ieiri I. Quantitative population pharmacokinetic analysis of pravastatin using an enterohepatic circulation model combined with pharmacogenomic information on SLCO1B1 and ABCC2 polymorphisms. J Clin Pharmacol. 2009;49:1309-1317.
19. Lilja JJ, Raaska K, Neuvonen PJ. Effects of orange juice on the pharmacokinetics of atenolol. Eur J Clin Pharmacol. 2005;61: 337-340. (Pubitemid 41569306)
20. Lappin G, Garner RC. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat Rev Drug Discov. 2003;2:233-240. (Pubitemid 37361669)
21. Lappin G, Garner RC. Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometry. Anal Bioanal Chem. 2004;378:356-364. (Pubitemid 40890243)
22. Aboagye EO, Price PM, Jones T. In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography. Drug Discov Today. 2001;6:293-302. (Pubitemid 32194666)
23. Bergström M, Grahnén A, Långström B. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol. 2003;59:357-366. (Pubitemid 37214939)
24. Grube M, Köck K, Karner S, et al. Modification of OATP2B1-mediated transport by steroid hormones. Mol Pharmacol. 2006;70:1735-1741.
25. Kusuhara H, Sekine T, Utsunomiya-Tate N, et al. Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999;274:13675-13680.
26. Shimizu M, Fuse K, Okudaira K, et al. Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos. 2005;33:1477-1481. (Pubitemid 41323995)
27. Beal SL, Sheiner LB. NONMEM User's Guides. San Francisco: NONMEM Project Group, University of California at San Francisco; 1998.
28. Murata K, Noda K. Pharmacokinetic analysis of an oral sustainedrelease diltiazem preparation using multifraction absorption models. Pharm Res. 1993;10:757-762. (Pubitemid 23152325)
29. Djebli N, Rousseau A, Hoizey G, et al. Sirolimus population pharmacokinetic/pharmacogenetic analysis and Bayesian modelling in kidney transplant recipients. Clin Pharmacokinet. 2006; 45:1135-1148. (Pubitemid 44631392)
30. Saint-Marcoux F, Marquet P, Jacqz-Aigrain E, et al. Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients. Clin Pharmacokinet. 2006;45:905-922. (Pubitemid 44299827)
31. Nozawa T, Nakajima M, Tamai I, et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther. 2002;302:804-813. (Pubitemid 34787251)
32. Kato Y, Miyazaki T, Kano T, Sugiura T, Kubo Y, Tsuji A. Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci. 2009;98:2529-2539.
33. Anderle P, Niederer E, Rubas W, et al. P-glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression levels. J Pharm Sci. 1998;87:757-762. (Pubitemid 28268577)
34. Gao J, Murase O, Schowen RL, Aubé J, Borchardt RT. A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res. 2001;18:171-176. (Pubitemid 32592596)
35. Caruso FS, Doshan HD, Hernandez PH, Costello R, Applin W, Neiss ES. Celiprolol: pharmacokinetics and duration of pharmacodynamic activity. Br J Clin Pract Suppl. 1985;40:12-16. (Pubitemid 16050218)
36. Kuo SM, Whitby BR, Artursson P, Ziemniak JA. The contribution of intestinal secretion to the dose-dependent absorption of celiprolol. Pharm Res. 1994;11:648-653. (Pubitemid 24171757)
37. Chen C. Some pharmacokinetic aspects of the lipophilic terfenadine and zwitterionic fexofenadine in humans. Drugs R Dev. 2007;8:301-314. (Pubitemid 47403125)
38. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999;27: 866-871. (Pubitemid 29347585)
39. Niemi M, Kivistö KT, Hofmann U, Schwab M, Eichelbaum M, Fromm MF. Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol. 2005;59:602-604. (Pubitemid 40632253)
40. Tahara H, Kusuhara H, Maeda K, Koepsell H, Fuse E, Sugiyama Y. Inhibition of oat3-mediated renal uptake as a mechanism for drugdrug interaction between fexofenadine and probenecid. Drug Metab Dispos. 2006;34:743-747.
41. Lappin G, Shishikura Y, Jochemesen R, et al. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur J Pharm Sci. 2010;40:125-131.
42. Yamazaki A, Kumagai Y, Yamane N, et al. Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-abelled drug and LC/MS/MS. J Clin Pharm Ther. 2010;35:169-175.
43. Lappin G, Kuhnz W, Jochemsen R, et al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin Pharmacol Ther. 2006;80:203-215. (Pubitemid 44313903)
44. International Transporter Consortium. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215-236.